Atlas Trials

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Clinical trial NCT06810050 · COMPLETED

Trial details

NCT number
NCT06810050
Sponsor
CAGE Bio Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Atopic Dermatitis (AD)
Start date
2024-12-18
Primary completion
2025-08-30
Enrollment
180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.